Active surveillance in patients with a PSA>10 ng/mL

Abstract

Introduction: The use of prostate-specific antigen (PSA) in active surveillance (AS) for prostate cancer is controversial. Some consider it an unreliable marker and others as sufficient evidence to exclude patients from AS. We analyzed our cohort of AS patients with a PSA over 10 ng/mL. Methods: We included patients who had clinical T1c-T2a Gleason ≤ 6 disease, and ≤3 positive cores with ≤50% core involvement at diagnostic biopsy and ≥2 total biopsies. Patients were divided into 3 groups: (1) those with baseline PSA>10 ng/mL, (2) those with a PSA rise>10 ng/mL during follow-up; and (3) those with a PSA10 ng/ mL and 157 had a PSA rise>10 ng/mL during surveillance. No difference in adverse his..